Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Modine Manufacturing Company (MOD) vs Viatris Inc (VTRS) Price & Performance

Modine Manufacturing CompanyTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Modine Manufacturing Company vs Viatris Inc — how do they compare? Modine Manufacturing Company trades at $184.22 (market cap $9.66B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.1× Modine Manufacturing Company's market cap, and Viatris Inc pays a 2.75% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Viatris Inc for 57 Days on average.

MODVTRS
Market Cap
$9.66B$20.03B
Volume
1,331,94614,109,977
Sector
IndustrialsHealth
52-Week High
$283.95$18.27
52-Week Low
$110.73$9.74
Typical Hold Time
33 Days57 Days
Enterprise Value
$10.09B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Modine Manufacturing Company

Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.

The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MOD
100% Buy0% Sell
Avg holding period · 33 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Modine Manufacturing Company

Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.

Read more on MOD →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →